[HTML][HTML] Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials

A Pormohammad, M Zarei, S Ghorbani, M Mohammadi… - Vaccines, 2021 - mdpi.com
The current study systematically reviewed, summarized and meta-analyzed the clinical
features of the vaccines in clinical trials to provide a better estimate of their efficacy, side …

[HTML][HTML] Virus-like particle vaccinology, from bench to bedside

MO Mohsen, MF Bachmann - Cellular & molecular immunology, 2022 - nature.com
Virus-like particles (VLPs) have become key tools in biology, medicine and even
engineering. After their initial use to resolve viral structures at the atomic level, VLPs were …

Carbohydrate-based macromolecular biomaterials

L Su, Y Feng, K Wei, X Xu, R Liu, G Chen - Chemical Reviews, 2021 - ACS Publications
Carbohydrates are the most abundant and one of the most important biomacromolecules in
Nature. Except for energy-related compounds, carbohydrates can be roughly divided into …

[HTML][HTML] Virus-like particles: Revolutionary platforms for developing vaccines against emerging infectious diseases

H Tariq, S Batool, S Asif, M Ali, BH Abbasi - Frontiers in microbiology, 2022 - frontiersin.org
Virus-like particles (VLPs) are nanostructures that possess diverse applications in
therapeutics, immunization, and diagnostics. With the recent advancements in biomedical …

COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies

K Rawat, P Kumari, L Saha - European journal of pharmacology, 2021 - Elsevier
Coronavirus Disease 2019 named as COVID-19 imposing a huge burden on public health
as well as global economies, is caused by a new strain of betacoronavirus named as SARS …

Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)-an update on the status

TM Abd El-Aziz, JD Stockand - Infection, Genetics and evolution, 2020 - Elsevier
Coronaviruses are a large group of viruses known to cause illnesses that vary between the
common cold and more severe diseases to include severe acute respiratory syndrome …

[HTML][HTML] Nanoparticle-based delivery systems for vaccines

R Bezbaruah, VP Chavda, L Nongrang, S Alom… - Vaccines, 2022 - mdpi.com
Vaccination is still the most cost-effective way to combat infectious illnesses. Conventional
vaccinations may have low immunogenicity and, in most situations, only provide partial …

Next‐generation vaccines: nanoparticle‐mediated DNA and mRNA delivery

W Ho, M Gao, F Li, Z Li, XQ Zhang… - Advanced healthcare …, 2021 - Wiley Online Library
Nucleic acid vaccines are a method of immunization aiming to elicit immune responses akin
to live attenuated vaccines. In this method, DNA or messenger RNA (mRNA) sequences are …

[HTML][HTML] Antiviral potential of nanoparticles—can nanoparticles fight against coronaviruses?

S Gurunathan, M Qasim, Y Choi, JT Do, C Park… - Nanomaterials, 2020 - mdpi.com
Infectious diseases account for more than 20% of global mortality and viruses are
responsible for about one-third of these deaths. Highly infectious viral diseases such as …

[HTML][HTML] Nanoparticle vaccines against infectious diseases

R Pati, M Shevtsov, A Sonawane - Frontiers in immunology, 2018 - frontiersin.org
Due to emergence of new variants of pathogenic micro-organisms the treatment and
immunization of infectious diseases have become a great challenge in the past few years. In …